Zobrazeno 1 - 10
of 40
pro vyhledávání: '"Alan B. Cooper"'
Autor:
Deodial Guiadeen, Shilan Liu, Jian Liu, Charles G. Garlisi, Arto D. Krikorian, Ronald M. Kim, Ying-Duo Gao, Peter Stivers, Hugh Y. Zhu, Alan B. Cooper, Rajan Anand, Philip E. Brandish, Younong Yu, Nathan Bays, Jiaqiang Cai, Ian Knemeyer, Erica Leccese, Zangwei Xu, Kevin M. Maloney, Alexandra Hicks, Sobhana Babu Boga, Chundao Yang, Joseph A. Kozlowski, My Sam Mansueto, Hao Wu, Thierry O. Fischmann, Desai Jagdish A, Jeremy Presland, Abdul-Basit Alhassan, Xiaolei Gao, Wang James J-S
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 27:3939-3943
8-Amino-imidazo[1,5- a ]pyrazine-based Bruton’s tyrosine kinase (BTK) inhibitors, such as 6 , exhibited potent inhibition of BTK but required improvements in both kinase and hERG selectivity (Liu et al., 2016; Gao et al., 2017). In an effort to mai
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::374dfa7e3c822671c1df7ad53a01c129
https://doi.org/10.1016/j.bmcl.2017.03.040
https://doi.org/10.1016/j.bmcl.2017.03.040
Autor:
Alan B. Cooper, Matthew J. Kostura, Michael Stocum, Michael A. Luther, Andy Anantha, Jedd Levine
Publikováno v:
Blood Cancer Discovery. 1:PO-47
BTM-3566 is a novel small-molecule compound with broad anticancer activity in hematologic and solid cancers, with exceptional activity against diffuse large B-cell lymphoma (DLBCL). The compound's mechanism of action (MoA) is dependent on activation
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::834ae4c6c69309d3f0d2c07ba7ff8b6d
https://doi.org/10.1158/2643-3249.lymphoma20-po-47
https://doi.org/10.1158/2643-3249.lymphoma20-po-47
Autor:
Nicolas Bruneau-Latour, Gerald W. Shipps, Chantal Grand-Maître, Martin Dery, Vibha Oza, Michael A. Luther, Lea Constantineau-Forget, Stephane Ciblat, Michael A. Patane, Jedd Levine, Edith Bellavance, Matthew J. Kostura, Alan B. Cooper, Arshad Siddiqui
Publikováno v:
Bioorganicmedicinal chemistry letters. 28(5)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::027ff0f55fdb19838d200a517fc88271
https://pubmed.ncbi.nlm.nih.gov/28844391
https://pubmed.ncbi.nlm.nih.gov/28844391
Autor:
Thomas S. Rush, Hussein Tawbi, Yongqi Deng, Wen-Jen Hwu, Paul Kirschmeier, Ryan J. Sullivan, Joseph Rubino, Ahmed A. Samatar, Lidia Robert, Gerald W. Shipps, Keith T. Flaherty, Donna Carr, Peter C.C. Fong, Antoni Ribas, Patrick Chun, Brian Long, Eric H. Rubin, Priya Dayananth, Ramesh K. Ramanathan, Ronnie Shapira-Frommer, Stergios J. Moschos, Blanca Homet Moreno, W. Robert Bishop, Alan B. Cooper, James E. Schiller, Alex A. Adjei, Nathan R. Miselis, Da Zhang
Publikováno v:
JCI Insight, Vol 3, Iss 4 (2018)
JCI insight, vol 3, iss 4
JCI insight, vol 3, iss 4
BACKGROUND. Constitutive activation of ERK1/2 occurs in various cancers, and its reactivation is a well-described resistance mechanism to MAPK inhibitors. ERK inhibitors may overcome the limitations of MAPK inhibitor blockade. The dual mechanism inhi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0f1125084220541ce8d767feec5c05a4
https://doaj.org/article/675b9e9f9e9e4e0f87e9c28de4f3db4b
https://doaj.org/article/675b9e9f9e9e4e0f87e9c28de4f3db4b
Autor:
Wang James J-S, Paul Kirschmeier, Ming Liu, Corey Strickland, Desai Jagdish A, Amin A. Nomeir, Alan B. Cooper, Viyyoor M. Girijavallabhan, Dinananth F. Rane, Hugh Y. Zhu
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 24:1228-1231
Tertiary hydroxyl class of C-imidazole bridgehead azaheptapyridine FPT inhibitors were prepared in an attempt to block in vivo oxidation of secondary hydroxyl series. One representative compound 5a exhibited potent enzyme (IC50 = 1.4 nM) and cellular
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::316a5dd688ac8613d61dbed78d3be26e
https://doi.org/10.1016/j.bmcl.2013.12.046
https://doi.org/10.1016/j.bmcl.2013.12.046
Autor:
Alan B. Cooper, Wang James J-S, William T. Windsor, Ahmed A. Samatar, Jerry Shipps, Yongqi Deng, Donna Carr, Desai Jagdish A, Hugh Y. Zhu
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 25:1627-1629
Starting from weak μM hits identified through affinity based Automated Ligand Identification System (ALIS) screenings, double digit nM hydroxyaniline amide Erk inhibitors were discovered. This class of compounds had the unique dual mechanism of inhi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5af2e112aa223b7c82d1c5c642a637b4
https://doi.org/10.1016/j.bmcl.2015.01.049
https://doi.org/10.1016/j.bmcl.2015.01.049
Autor:
Shuxia Zhao, Paul Kirschmeier, Ulrike Philippar, Li Xiao, Wang James J-S, Boga Sobhana Babu, Pierre Daublain, Phieng Siliphaivanh, Priya Dayananth, Clifford Restaino, Donna Carr, Lata Jayaraman, Xiaolei Gao, Marc Pelletier, Ling Zhang, Bart Lutterbach, Erick J. Morris, Stuart Black, Rumin Zhang, Weihong Jin, Ahmed A. Samatar, Joe Kelly, Daniel J. Hicklin, Alan B. Cooper, Leigh Zawel, Liang Zhu, Brian Long, Elaine M. Pinheiro, Hugh Y. Zhu, Sharda Jha, Stephen Fawell, Sunil Paliwal, D. Gary Gilliland, Jenny Liu, William T. Windsor, David J. Witter, Edward DiNunzio, Yongi Deng, W. Robert Bishop, Minilik Angagaw, Desai Jagdish A, Alan Hruza, Gerald W. Shipps
Publikováno v:
Cancer Discovery. 3:742-750
The high frequency of activating RAS or BRAF mutations in cancer provides strong rationale for targeting the mitogen-activated protein kinase (MAPK) pathway. Selective BRAF and MAP-ERK kinase (MEK) inhibitors have shown clinical efficacy in patients
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::00ca7ac16344cf7d4ebc028f039418f5
https://doi.org/10.1158/2159-8290.cd-13-0070
https://doi.org/10.1158/2159-8290.cd-13-0070
Autor:
Sobhana Babu Boga, Ying-Duo Gao, Jiaqiang Cai, Thierry O. Fischmann, Wensheng Yu, Chundao Yang, Oleg Selyutin, Shilan Liu, Nathan Bays, Peter Stivers, Hugh Y. Zhu, Joeseph A. Kozlowski, Philip E. Brandish, Rajan Anand, Hao Wu, Ronald M. Kim, James Wang, Alan B. Cooper, Younong Yu, Erica Leccese, Ian Knemeyer, Zangwei Xu, Deodial Guiadeen, Kevin M. Maloney, Jie Zhang-Hoover, Alexandra Hicks, Charles G. Garlisi, Jeremy Presland, My Sam Mansueto, Abdul-Basit Alhassan, Xiaolei Gao, Arto D. Krikorian, Jian Liu
Publikováno v:
Bioorganicmedicinal chemistry letters. 27(6)
We report the design and synthesis of a series of novel Bruton's Tyrosine Kinase (BTK) inhibitors with a carboxylic acid moiety in the ribose pocket. This series of compounds has demonstrated much improved off-target selectivities including adenosine
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::85aa9014e3762fe9f863175d58d9b47e
https://pubmed.ncbi.nlm.nih.gov/28254166
https://pubmed.ncbi.nlm.nih.gov/28254166
Autor:
Joseph A. Kozlowski, Hao Wu, Chundao Yang, Jie Zhang-Hoover, Thierry O. Fischmann, Jeremy Presland, Sobhana Babu Boga, Allard Kaptein, Philip E. Brandish, Ying-Duo Gao, Kevin M. Maloney, Arto D. Krikorian, Shilan Liu, My Sam Mansueto, Abdul-Basit Alhassan, Henry M. Vaccaro, Diep Vu-Pham, Erica Leccese, Ronald M. Kim, Alexandra Hicks, Alan B. Cooper, Charles G. Garlisi, Jian Liu, Nathan Bays, Hans C.A. Raaijmakers, Jos de Man, Peter Stivers, Wang James J-S, Deodial Guiadeen, Xiaolei Gao, Viktor Hornak, Younong Yu, Ian Knemeyer, Zangwei Xu
Publikováno v:
ACS medicinal chemistry letters. 7(2)
Bruton's tyrosine kinase (BTK) is a Tec family kinase with a well-defined role in the B cell receptor (BCR) pathway. It has become an attractive kinase target for selective B cell inhibition and for the treatment of B cell related diseases. We report
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aef21521484b31fc31f3730ab2c22387
https://pubmed.ncbi.nlm.nih.gov/26985298
https://pubmed.ncbi.nlm.nih.gov/26985298
Autor:
Anthony Regina, Alan B. Cooper, Martine Brault, Stephane Ciblat, Meztli Arguello, Arshad Siddiqui, Michael A. Luther, Jedd Levine, Vibha Oza, Matthew J. Kostura, Peter W. White, Edith Bellavance
Publikováno v:
Clinical Cancer Research. 23:45-45
Aberrant regulation of cell cycle control, integration of signals from oncogenic signaling pathways, and cancer cell metabolism play a key role in the pathogenesis of multiple hematologic malignancies and solid tumors. BTM-3528 is an orally available
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ca1857c6f1af18f1268453aac5760a6a
https://doi.org/10.1158/1557-3265.hemmal17-45
https://doi.org/10.1158/1557-3265.hemmal17-45